AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06174584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: Hypertonic saline
Study NCT06174584 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow Milk
Description: Cow Milk
Study NCT06174311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Cognitive Bias Modification
Description: The intervention comprises three sessions and is provided online. Each session consists of two different tasks. To prevent order effects, these tasks will be presented to each participant in a random sequence. One of the tasks involves uncertain scenarios based on a scenario paradigm. At the end of these scenarios, participants will be asked to complete a missing letter in a word that in the scenario, followed by a comprehension question related to the scenario interpretation. Following each question, feedback will be provided regarding the correctness of the response. The other task is a word-sentence pair paradigm, where participants will be asked to assess whether these pairs are related, and feedback will also be provided.
Study NCT05527379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: When the patient is ready to have the CIP procedure the tablet will be presented to him so that he can view and choose the immersive film that suits him best.~Before fitting the virtual reality helmet and the start of the film, the patient's anxiety will be evaluated by ENS on a scale of 0 to 10 . The patient's anxiety will also be evaluated at the end of the procedure.~The patient will be contacted by telephone by an investigator between D+1 and D+5 in order to reassess and remotely from the pose, his memorization of the gesture and to look for adverse events.
Study NCT05920980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Patients in the lidocaine groups, lidocaine 1.5mg/kg/h was continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg), diluted to 200ml with saline until 72h after surgery. Blood samples will be collected from some patients in the lidocaine group for the measurement of lidocaine plasma concentration.
Study NCT05920980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
Study NCT04918784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restrata®
Description: Restrata® is a sterile, single use device intended for use in local management of wounds. Restrata® is a soft, white, conformable, non-friable, absorbable matrix that provides a moist environment for the body's natural healing process to occur. Restrata® is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native extracellular matrix.
Study NCT04918784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Dressing
Description: Alginate or Foam wound dressing is intended to manage wounds.
Study NCT06258590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation
Description: Patients will receive non invasive vagus nerve stimulation via electrodes attached to the ear.
Study NCT05591027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centella asiatica product
Description: A sachet of powdered product containing 4 g of a dried hot water extract of Centella asiatica as the active ingredient, combined with inactive ingredients (excipients) for color and taste dissolved in 10 oz of warm or room temperature water and consumed orally.
Study NCT05591027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A sachet of powdered inactive ingredients (excipients) for color and taste identical in volume to those found in the active arm (CAP) dissolved in 10 oz of warm or room temperature water and consumed orally.
Study NCT04563221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization
Description: Prostatic artery embolization is performed using LC Bead LUMI, which is the investigational device. The particles are administered to the prostatic arteries using either a balloon occlusion or standard microcatheter. Follow-up is performed at 1 month, 6 months, 12 months, and 24 months after intervention.
Study NCT06263621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Standard
Description: The two cafes will offer entrees in two sizes, a smaller and larger size. In the intervention cafe, the smaller size will be labeled Standard during the intervention period, and Small during all other times. In the control cafe, the smaller size will always be labeled Small. The larger size will always be labeled Large for both cafes during the duration of the study.
Study NCT05888506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester
Description: Participants will consume the ketone ester beverage produced by KetoneAid prior to bedtime. Participants will consume 60 mL (30 grams ketones) of the ketone beverage.
Study NCT05888506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume the placebo supplement prior to bedtime. The placebo supplement will be a ketone ester-free, taste and viscosity-matched, beverage produced by KetoneAid.
Study NCT06380218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrional and physical activity program
Description: Nutritional prevention and physical activity workshops associated with a substitution of saturated and/or trans fatty acids by cis-unsaturated acids via the consumption of Primevère margarine to influence lifestyle habits, quality of life and improvement of the lipid profile of women with cardiovascular risk
Study NCT05282797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANEB-001
Description: Experimental Treatment
Study NCT06141694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The LIBERTY® Robotic System
Description: The LIBERTY® Robotic System is intended for use in the remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters, to facilitate navigation to anatomical targets in the peripheral vasculature.~The LIBERTY® Robotic System is not intended for coronary or neurointerventional procedures.
Study NCT05282797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT06363877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of dilute aqueous povidone-iodine solution allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the povidone-iodine solution then wash-out with 2L of normal saline followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL povidone-iodine solution, suctioned, then washed-out with 500 mL normal saline.
Study NCT06363877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of normal saline allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the solution, wash-out with 2L of normal saline, followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL normal saline solution, suctioned, then washed-out with 500 mL normal saline.
Study NCT06527313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Special Exercises
Description: Subjects in the control group will be shown home exercises customized for knee osteoarthritis and asked to continue them.~Specialized Home Exercises for the Knee Joint~1. Lumbar extensor stretching, Hamstring stretching, hip flexors stretching, TFL stretching,~2. Straight leg raise (lying on back and side)~3. Bridge exercise~4. Drawing circles while lying on your back and side~5. Knee flexion-extension~6. Weight bearing exercises~7. Tiptoe exercise~8. Step climbing and descending exercise~9. Terminal knee extension~10. Strengthening the muscles around the hips
Study NCT04799210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eximis CS (Contained Segmentation) System
Description: Containment, segmentation and extraction of uterine tissue in pre-menopausal women undergoing laparoscopic hysterectomy or myomectomy for non-cancer indications.
Study NCT05698446 — intervention group
Intervention type: PROCEDURE
Intervention: Modified Broström + Suture tape augmentation operation
Description: Patients with CLAI and GJL will accept the Modified Broström + Suture tape augmentation operation
Study NCT05698446 — intervention group
Intervention type: PROCEDURE
Intervention: Anatomic reconstruction operation
Description: Anatomic reconstruction operation
Study NCT04791761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study NCT04791761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study NCT04791761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study NCT04791761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study NCT04791761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Study NCT04791761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid disposal pouch
Description: Half of the opioid group will be randomized assigned to an opioid disposal pouch arm. This pouch is a drug deactivation system that can be disposed in the trash in a household.
Study NCT04791761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid disposal education
Description: An opioid disposal education document will be provided to all families in the opioid group. This education document has information on unused or expired prescription medication disposal and specific information about permanent collection sites within our health system, drug take-back locations, drug take back day, and disposing at home.
Study NCT06022757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous
Study NCT06022757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection
Description: KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
Study NCT04779970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation of ongoing treatment
Description: Cessation of ongoing treatment
Study NCT05226455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax + azacitidine +/- donor lymphocyte infusion
Description: Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)
Study NCT05199779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Intervention Leveraging an Ultra-Brief Self-Compassion Exercise
Description: This 20-second contemplative exercise includes draws from the science of habit formation and includes elements of self-soothing touch, somatic experiencing, and mindful self-compassion.
Study NCT05199779 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Finger-Tapping Active Control
Description: This 20-second finger tapping exercise involves touching each finger to the thumb on one hand and repeating for twenty seconds. This intervention was designed to control for the potential effect of assessment on outcomes, the effect of having an activity to do for the duration of the intervention (4 weeks), regression to the mean, time, or other nonspecific factors.
Study NCT05061316 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nestlé Impact Advanced Recovery
Description: Immunonutrition drink that helps support the immune system: reduces risk of prolonged hospital stay and complications after surgery.
Study NCT05333406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN001
Description: EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg
Study NCT05333406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN001
Description: EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg
Study NCT05154682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: Oxycodone will be given every 4 hours as needed for 2 weeks after surgery
Study NCT05154682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 500Mg Tab
Description: Acetaminophen will be taken every 4 hours for 2 weeks after surgery
Study NCT05154682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500 Mg
Description: Naproxen will be taken every 12 hours for 2 weeks after surgery
Study NCT06514144 — intervention group
Intervention type: DRUG
Intervention: BGF
Description: budesonide/glycopyrrolate/formoterol fumarate
Study NCT04945317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ROSE (presence of cytotech) & liquid prep
Description: Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
Study NCT04945317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NO-ROSE (absence of cytotech) & liquid prep
Description: Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
Study NCT04945317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ROSE (presence of cytotech) & tissue clot sample
Description: Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
Study NCT04945317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NO-ROSE (absence of cytotech) & tissue clot sample
Description: Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
Study NCT04977050 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quidel quickvue antigen test for COVID-19
Description: rapid antigen test on nasal swab specimen for COVID-19
Study NCT05600374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bossdevice
Description: The bossdevice is a real-time digital signal processor consisting of hardware and software algorithms. It is designed to read-in a real-time raw data stream from a bio-signal amplifier (electroencephalography, EEG), to continuously analyze this data and to detect patterns based on oscillations in different frequencies. When such a specific bio-signal pattern is detected, the device indicates this through a standard output port. This enables a connected device to know with millisecond accuracy when a specific biosignal pattern occurs.
Study NCT05566665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of blood and bronchoalveolar samples to study Pharmacokinetics of ceftazidime/avibactam, meropenem/varbobactam, ceftolozane/tazobactam, or cefiderocol
Description: The antibiotic treatment with ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will follow the standard clinical practice.~The concentration of ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, or cefiderocol will be measured at specific timepoints in plasma samples and bronchoalveolar lavage samples, and a PK analysis and modeling will be carried out .
Study NCT05724251 — intervention group
Intervention type: OTHER
Intervention: healthy
Description: no intervention
Study NCT06310291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VTP-1000
Description: Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component
Study NCT06310291 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Intramuscular (IM) injection comprised of saline solution
Study NCT05724251 — intervention group
Intervention type: OTHER
Intervention: periodontitis
Description: no intervention
Study NCT06580288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: 10mg or 20mg
Study NCT06580288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg or 20mg
Study NCT06579209 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide adenine dinucleotide
Description: Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo
Study NCT04644042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glenohumeral arthroscopy + Arthroscopic Subacromial Decompression
Description: In addition to the glenohumeral athroscopy a lateral portal will be used to access the subacromial space. The subacromial space will be decompressed with removal of inflamed bursal tissue and acromioclavicular osteophytes, release of the coracoacromial ligament, and, if deemed necessary by the surgeon, acromioplasty performed ad modum Caspari.
Study NCT04644042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glenohumeral arthroscopy + lateral skin incision
Description: Glenohumeral arthroscopy is performed as a standard investigational procedure. The patient is put under general anesthesia and positioned in the 'beach chair position'. An anteriorsuperior portal and a posterior mid-glenoid portal are used as entry to the joint. The following structures are investigated as a minimum: the articular surface of the humeral head and the glenoid, labrum, the long biceps tendon and its attachment at the superior labrum, the undersurface of the supraspinatus and the infraspinatus tendon, the subscapularis tendon and the glenohumeral ligaments. To allow for the best possible blinding a skin incision (mimicking the one used for arthroscopic subacromial decompression) is performed on the lateral side of the shoulder of the participants in the control group. The obturator is introduced in the subcutaneous tissue and a slight circular release is performed. The deltoid fascia is not perforated and the subacromial space is not entered.
Study NCT05191758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FPP supplement
Description: Participants will take the supplements per randomization
Study NCT06213948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 MG
Description: Mirtazapine~* Commercial name: Remeron® SolTab~* Pharmaceutical form: film-coated tablets (15 mg)
Study NCT05550454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Mechanical Ventilation
Description: Ventilation settings:~Mode: (S)Continuous Mandatory Ventilation Rate: 10 b/min. Tidal Volume: 500 ml (male), 450 ml (female) I:E=1:1 Positive end expiratory pressure (PEEP): 5 cmH2O Flow trigger: off Oxygen: 100% Alarms: Pressure 70 cmH20, Tidal volume 100 \~ 1,000 ml
Study NCT05550454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Ventilation
Description: Ambu-bagging (It is recommended in the guidelines as a ventilation method.) Methods: 10 times per minutes by medical personnel